Plasmodium falciparum biomolecules (P. falciparum biomolecules)

Plasmodium falciparum biomolecules encompass the entire suite of proteins, enzymes, and nucleic acids produced by the Plasmodium falciparum parasite, the primary causative agent of severe malaria in humans [1]. These biomolecules are essential for the parasite's survival, facilitating its complex life cycle across mosquito and human hosts, including the invasion of red blood cells and the degradation of host hemoglobin [2]. Key therapeutic targets within this group include enzymes such as dihydrofolate reductase (DHFR) and the cytochrome bc1 complex, as well as pathways involved in heme detoxification [3]. Antimalarial drugs like artemisinins, chloroquine, and atovaquone exert their effects by binding to or inhibiting these specific biomolecules, thereby disrupting parasite metabolism or inducing lethal oxidative stress [4]. However, the rapid evolution of these biomolecules through genetic mutations has led to widespread drug resistance, necessitating the continuous identification of novel molecular targets within the parasite's proteome [5]. Furthermore, certain biomolecules like histidine-rich protein 2 serve as critical diagnostic markers for detecting infection in clinical settings [6]. The study of these molecules is also pivotal for vaccine development, targeting surface proteins to prevent host cell entry [7].

Other names

Plasmodium falciparum proteomeMalarial parasite proteinsP. falciparum antigensMalarial targets

Inhibition of heme biocrystallization, inhibition of dihydrofolate reductase, inhibition of mitochondrial electron transport, induction of oxidative stress via free radicals, and inhibition of protein synthesis.